Treats elevated intraocular pressure. ANDA 202053, held by Regcon Holdings. Dorzolamide Hydrochloride.
As of Nov 16, 2026, ANDA 202053 (Dorzolamide Hydrochloride), held by Regcon Holdings, was first approved by FDA on Sep 11, 2014, with 1 approved supplement and 0 published complete response letters.
Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride ophthalmic solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 11, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dorzolamide HydrochlorideEQ 2% BASE · solution/drops;ophthalmic | Dorzolamide Hydrochloride | Rx |
| Feb 20, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 11, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters